Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Large study identifies DLCBL patients at high risk of mortality
Key clinical point: Age at diagnosis, married status, black race, and higher tumor stage are associated with an increased risk of DLBCL-specific mortality.
Major finding: The significant hazard ratios for cancer specific-mortality by tumor stage were: stage II, HR: 1.143; III, HR: 1.46; IV, HR: 1.96.
Study details: Review of the risk factors for cancer specific mortality and cardiovascular mortality in 62,950 cases of DLBCL in China.
Disclosures: The study was sponsored Gannan Medical University and the Health and Planning Commission Research Project of Jiangxi Province, China. The authors reported they had no conflicts of interest.
Zhao J et al. Clinical Lymphoma, Myeloma and Leukemia. 2020;doi.org/10.1016/j.clml.2020.06.005.